Litcius/Paper detail

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo, Kaiko Kunii, Kristy Kuplast‐Barr, Bin Gui, Alvin Lu, Jennifer R. Molina, Elena Minissale, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina Nayak, Ellen Bamberg, Jan-Rung Mo, W. David Church, Ahmed S.A. Mady, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack

2021Cancer Cell183 citationsDOI

Topics & Concepts

Immune systemBiologyInterferonCancer cellCancer researchSignal transductionAcquired immune systemCancerImmunityNucleic acidCell signalingCancer immunotherapyImmunotherapyCell biologyImmunologyBiochemistryGeneticsPARP inhibition in cancer therapyinterferon and immune responsesCancer Immunotherapy and Biomarkers
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity | Litcius